Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/21548
Başlık: Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tibbi Onkoloji Bilim Dalı.
0000-0002-9732-5340
0000-0003-2501-3097
0000-0002-2382-290X
Demiray, Mutlu
Ulukaya, Engin
Arslan, Murat
Gökgöz, Sehsuvar
Saraydaroğlu, Ozlem
Ercan, İlker
Evrensel, Türkkan
Manavoğlu, Osman
AAJ-1027-2021
M-8060-2019
K-5792-2018
AAH-9701-2021
Anahtar kelimeler: Oncology
Chemotherapy
Neoadjuvant
ApoptosisBreast cancer
M30
Cytokeratin 18
Apoptosis
Breast cancer
Assay
Expression
Proliferation
Tumors
Preoperative chemotherapy
Yayın Tarihi: 2006
Yayıncı: Taylor & Francis
Atıf: Demiray, M. vd. (2006). ''Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study''. Cancer Investigation, 24(7), 669-676.
Özet: The M30-monoclonal antibody recognizes a neo-epitope of cytokeratin 18 which is formed after caspase-cleavage during apoptosis. Caspase-cleaved cytokeratin 18 is released from apoptotic cells into circulation. The aim of this study was to evaluate the relationship between M30-antigen level and chemotherapy response in neoadjuvant treatment of breast cancer. Forty-two patients with invasive breast carcinoma received 4 cycles of anthracycline based neoadjuvant chemotherapy. Serum samples were obtained for assessment of M30-antigen levels before the administration of first chemotherapy cycle (baseline), and then after 24 and 48 hours for determination of chemotherapy induced apoptosis. M30-antigen levels at 24 and 48 hours were found to be significantly higher than baseline (p < 0.001, p = 0.003, respectively). M30-antigen levels in responders showed statistically significant increases at 24 and 48 hours (p < 0.001; p = 0.004, respectively), while statistically significant increases were not observed in nonresponders. Percentage change of M30-antigen levels was significantly higher in responders than nonresponders at 24 hours (p = 0.020). In conclusion, our study revealed a significant relationship between increases of M30-antigen levels in serum and overall response to therapy.
URI: https://doi.org/10.1080/07357900600981307
https://www.tandfonline.com/doi/full/10.1080/07357900600981307
http://hdl.handle.net/11452/21548
ISSN: 0735-7907
1532-4192
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.